Novavax, Inc. (NVAX)
After hours:
| Previous close | 6.02 |
| Open | 6.07 |
| Bid | 5.80 x 1200 |
| Ask | 5.90 x 3200 |
| Day's range | 5.77 - 6.16 |
| 52-week range | 5.68 - 83.54 |
| Volume | |
| Avg. volume | 6,824,111 |
| Market cap | 498.081M |
| Beta (5Y monthly) | 1.78 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -8.52 |
| Earnings date | 08 May 2023 - 12 May 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 50.80 |
- Motley Fool
1 Green Flag and 1 Red Flag for Novavax
Novavax (NASDAQ: NVAX) has had more than its share of ups and downs over the past few years -- and investors have been along for the ride. The stock soared 2,700% in 2020 as the company brought its coronavirus vaccine candidate through late-stage clinical trials. The biotech company's vaccine reached commercialization later than rivals.
- Zacks
Novavax (NVAX) Gains But Lags Market: What You Should Know
Novavax (NVAX) closed at $5.97 in the latest trading session, marking a +1.19% move from the prior day.
- Motley Fool
2 Growth Stocks That Are Trading at a Huge Discount Right Now -- Maybe Rightfully So
On that note, here are a couple of severely beaten-down growth stocks that are popular among investors, but only one of them has a credible path to stay in business. With ambitions to become the world's biggest seller of legal cannabis products, Tilray Brands (NASDAQ: TLRY) is also a growth stock that's remarkably inexpensive. Despite reporting $144 million in revenue for its fiscal second quarter and free cash flow (FCF) of $25.4 million, its shares are down 42.7% in the last three years because of persistent unprofitability and wild oversupply compared to demand across several continents.
